Table 4.

Antitubercular agents inhibiting other mycobacterial targets.

No.	Target	Scaffold	SAR plan from hit	Most advanced analogue	In vivo efficacy	Ref.
1.1	Rv0577	Pyrimidine imidazoles			Noa	(Pethe et al., 2010)
2.1	FtsZ	Benzimidazoles			N/Db	(Kumar et al., 2011; Awasthi et al., 2013)
3.1	EthR	N-phenylphenoxy acetamides			N/D	(Flipo et al., 2012)
4.1	LepB	Arylhydrazones			N/D	(Bonnett et al., 2016)
5.1	CysM	Diphenyl ureas			N/D	(Brunner et al., 2016)
6.1	BioA	Benzoyl piperazines			N/D	(Park et al., 2015; Liu et al., 2017)
7.1	IMPDH	Indazole sulfonamides			No	(Park et al., 2017)
7.2		Benzoxazoles			N/D	(Chacko et al., 2018)
8.1	PknA PknB	Pyrazolyl pyrimidinamine			N/D	(Wang et al., 2017)
9.1	CorA	Pyrimidinetrione amides			No	(Park et al., 2019)
10.1	DosS DosT	Ureas			N/D	(Zheng et al., 2020)

^aNo, inactive in an acute TB infection mouse model; ^bN/D, not determined.